Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
ATNM — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

2.63

Margin Of Safety %

Put/Call OI Ratio

0.02

EPS Next Q Diff

-0.06

EPS Last/This Y

0.18

EPS This/Next Y

0.56

Price

0.8

Target Price

6.5

Analyst Recom

1

Performance Q

-34.64

Upside

-3,381.3%

Beta

0.02

Ticker: ATNM




18 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-07-14ATNM0.9070.030.002218
2026-07-15ATNM0.91020.020.002412
2026-07-16ATNM0.89010.020.002494
2026-07-17ATNM0.91670.020.002515
2026-07-20ATNM0.8830.020.002201
2026-07-21ATNM0.910.020.002247
2026-07-22ATNM0.89890.020.002293
2026-07-23ATNM0.8910.020.002293
2026-07-24ATNM0.860.020.002305
2026-07-27ATNM0.85220.020.002331
2026-07-28ATNM0.85830.020.002331
2026-07-29ATNM0.83720.020.002352
2026-07-30ATNM0.84010.020.002352
2026-07-31ATNM0.8450.020.002352
2026-08-03ATNM0.8140.020.002362
2026-08-04ATNM0.82340.020.002382
2026-08-05ATNM0.7460.020.002397
2026-08-07ATNM0.79990.020.002526
DateSymbolLatestP/C OIP/C VolTotal OI
18 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-07-14ATNM0.919.1- -0.91
2026-07-15ATNM0.929.1- -0.91
2026-07-16ATNM0.899.1- -0.91
2026-07-17ATNM0.929.1- -0.91
2026-07-20ATNM0.889.1- -0.91
2026-07-21ATNM0.909.1- -0.91
2026-07-22ATNM0.929.1- -0.91
2026-07-23ATNM0.899.1- -0.91
2026-07-24ATNM0.869.1- -0.91
2026-07-27ATNM0.849.1- -0.91
2026-07-28ATNM0.859.1- -0.91
2026-07-29ATNM0.849.1- -0.91
2026-07-30ATNM0.859.1- -0.91
2026-07-31ATNM0.859.1- -0.91
2026-08-03ATNM0.819.1- -0.91
2026-08-04ATNM0.819.1- -0.91
2026-08-05ATNM0.759.1- -0.91
2026-08-06ATNM0.779.1- -0.91
2026-08-07ATNM0.809.1- -0.91
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-07-14ATNM0.00-0.913.00
2026-07-15ATNM0.00-0.913.00
2026-07-16ATNM0.00-0.913.00
2026-07-17ATNM0.00-0.913.00
2026-07-20ATNM0.00-0.913.00
2026-07-21ATNM0.00-0.913.00
2026-07-22ATNM0.00-0.913.00
2026-07-23ATNM0.00-0.913.00
2026-07-24ATNM0.00-0.913.00
2026-07-27ATNM0.00-0.912.63
2026-07-28ATNM0.00-0.912.63
2026-07-29ATNM0.00-0.912.63
2026-07-30ATNM0.00-0.912.63
2026-07-31ATNM0.00-0.912.63
2026-08-03ATNM0.00-0.972.63
2026-08-04ATNM0.00-0.972.63
2026-08-05ATNM0.00-0.972.63
2026-08-06ATNM0.00-0.972.63
2026-08-07ATNM0.00-0.972.63
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

-0.18

Avg. EPS Est. Current Quarter

-0.2

Avg. EPS Est. Next Quarter

-0.24

Insider Transactions

Institutional Transactions

-0.97

Beta

0.02

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

6

Growth Score

25

Sentiment Score

18

Actual DrawDown %

94.7

Max Drawdown 5-Year %

-94.8

Target Price

6.5

P/E

Forward P/E

PEG

P/S

277.96

P/B

10.86

P/Free Cash Flow

EPS

-0.75

Average EPS Est. Cur. Y​

-0.91

EPS Next Y. (Est.)

-0.35

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-26078.89

Relative Volume

1.1

Return on Equity vs Sector %

-100

Return on Equity vs Industry %

-100

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.07

EBIT Estimation

ATNM Healthcare
$0.80
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
0/20
Pullback
18/25
Volume
4/15
Valuation
12/20
TP/AR
4/10
Options
7/10
RSI
35.7
Range 1M
20.1%
Sup Dist
5%
🚀
Momentum Growth
Ride accelerating trends
N/A
32 /100
WEAK
Momentum
0/25
Growth
20/30
Estimates
2/20
Inst/Vol
2/15
Options
8/10
EPS Yr
16.5%
EPS NY
26.4%
52W%
5.9%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +712.5% upside
Quality
2/30
Valuation
16/30
Growth
16/25
Stability
5/10
LT Trend
1/5
Upside
+712.5%
Quality
6
ATNM — P/E HistoricalBiotechnology
Actinium Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 25
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
ATNM

Latest News

Caricamento notizie per ATNM
stock quote shares ATNM – Actinium Pharmaceuticals Inc Stock Price stock today
news today ATNM – Actinium Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ATNM – Actinium Pharmaceuticals Inc yahoo finance google finance
stock history ATNM – Actinium Pharmaceuticals Inc invest stock market
stock prices ATNM premarket after hours
ticker ATNM fair value insiders trading